Siemens' DPC (Diagnostic Products Corporation) buy gets German OK:
This article was originally published in Clinica
Siemens' proposed acquisition of Los Angeles, California-based immunodiagnostics company Diagnostic Products Corporation (DPC) has received clearance from German antitrust authorities. The news comes shy of a week after the US Federal Trade Commission gave the go-ahead to the $1.86bn transaction (see Clinica No 1211, p 14). The companies still require shareholder approval before closing the acquisition.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.